Get the Stockscreener App
16.30
3.62%
0.57
Pre-market:
16.30
Cullinan Therapeutics Inc stock is traded at $16.30, with a volume of 845.04K.
It is up +3.62% in the last 24 hours and up +32.20% over the past month.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.
See More
Previous Close:
$15.73
Open:
$15.92
24h Volume:
845.04K
Relative Volume:
0.94
Market Cap:
$962.94M
Revenue:
-
Net Income/Loss:
$-153.16M
P/E Ratio:
-4.4173
EPS:
-3.69
Net Cash Flow:
$-134.48M
1W Performance:
+13.51%
1M Performance:
+32.20%
6M Performance:
+135.89%
1Y Performance:
+100.49%
1-Day Range:
$15.54
$16.44
1-Week Range:
$13.67
$16.74
52-Week Range:
$5.68
$16.74
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
Name
Cullinan Therapeutics Inc
Sector
Industry
Phone
617-410-4650
Address
ONE MAIN STREET, CAMBRIDGE
Compare CGEM vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
16.30 | 929.27M | 0 | -153.16M | -134.48M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-17-26 | Initiated | Citigroup | Buy |
| Feb-02-26 | Initiated | Guggenheim | Buy |
| Aug-21-25 | Resumed | H.C. Wainwright | Buy |
| Jun-11-25 | Resumed | Stifel | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| May-01-24 | Initiated | Stifel | Buy |
| Apr-15-24 | Initiated | William Blair | Outperform |
| Feb-15-24 | Initiated | Wedbush | Outperform |
| Jun-15-23 | Initiated | TD Cowen | Outperform |
| Nov-21-22 | Initiated | BTIG Research | Buy |
| Apr-27-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Feb-02-21 | Initiated | Evercore ISI | Outperform |
| Feb-02-21 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-02-21 | Initiated | SVB Leerink | Outperform |
| Feb-01-21 | Initiated | H.C. Wainwright | Buy |
View All
Cullinan Therapeutics Inc Stock (CGEM) Latest News
[SCHEDULE 13G] Cullinan Therapeutics, Inc. Passive Investment Disclosure (>5%) - Stock Titan
CGEM: Transformational milestones and pivotal data for autoimmune and AML programs expected by 2026 - TradingView
CGEM Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Cullinan Therapeutics (CGEM) Stock Analysis: Exploring A 101% Upside Potential - DirectorsTalk Interviews
Cullinan Therapeutics (NASDAQ:CGEM) Shares Up 7.6%Here's Why - MarketBeat
Cullinan Therapeutics executives to join major healthcare conference fireside chats - Traders Union
Cullinan Therapeutics (NASDAQ:CGEM) Insider Sells $25,169.20 in Stock - MarketBeat
Insider Sell: Jennifer Michaelson Sells Shares of Cullinan Thera - GuruFocus
Cullinan Therapeutics (CGEM) CSO sells 1,780 shares in Rule 10b5-1 trade - Stock Titan
CGEM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Cullinan Therapeutics (NASDAQ:CGEM) Insider Jennifer Michaelson Sells 1,752 Shares - MarketBeat
Insider Selling: Cullinan Therapeutics (NASDAQ:CGEM) Insider Sells 3,601 Shares of Stock - MarketBeat
Insider Selling: Cullinan Therapeutics (NASDAQ:CGEM) Insider Sells $66,301.54 in Stock - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) CEO Nadim Ahmed Sells 13,515 Shares - MarketBeat
Cullinan Therapeutics (CGEM) CSO sells 5,353 shares under 10b5-1 plan - Stock Titan
Cullinan Therapeutics (CGEM) CMO sells shares to cover RSU tax bill - Stock Titan
[Form 4] Cullinan Therapeutics, Inc. Insider Trading Activity - Stock Titan
Jennifer Michaelson sells shares under 10b5-1 (CGEM) - Stock Titan
Cullinan Therapeutics (NASDAQ:CGEM) Hits New 12-Month HighWhat's Next? - MarketBeat
Cullinan Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Cullinan Therapeutics: Thesis Strengthening For T-Cell Engager Specialist (NASDAQ:CGEM) - Seeking Alpha
Jennifer Michaelson Sells 11,742 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Insider Jeffrey Alan Jones Sells 4,982 Shares - MarketBeat
Insider Selling: Cullinan Therapeutics (NASDAQ:CGEM) CFO Sells 4,398 Shares of Stock - MarketBeat
Cullinan Therapeutics (CGEM) CMO sells 4,982 shares for RSU tax obligations - Stock Titan
Cullinan Therapeutics (CGEM) CSO exercises options and sells 11,742 shares - Stock Titan
Cullinan Therapeutics (CGEM) CLO sells 3,742 shares to cover tax - Stock Titan
Cullinan Therapeutics (CGEM) CEO sells shares to cover RSU tax bill - Stock Titan
Cullinan Therapeutics (CGEM) CFO sells shares to cover RSU tax bill - Stock Titan
CGEM (NASDAQ: CGEM) Form 144 shows 1,752-share proposed resale; insider sales listed - Stock Titan
Cullinan Therapeutics Inc expected to post a loss of 81 cents a shareEarnings Preview - TradingView
Is Cullinan Therapeutics Inc. benefiting from innovation trendsCEO Change & Detailed Earnings Play Strategies - mfd.ru
Cullinan Therapeutics (NASDAQ:CGEM) Cut to Hold at Zacks Research - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Stock Rating Lowered by Zacks Research - MarketBeat
Cullinan Therapeutics, Inc. (CGEM) Investor Outlook: A Biotech With 120% Upside Potential - DirectorsTalk Interviews
Will Cullinan Therapeutics Inc. stock recover faster than peersJuly 2025 PreEarnings & Smart Money Movement Alerts - mfd.ru
What is the long term forecast for Cullinan Therapeutics Inc. stockJuly 2025 Sentiment & Detailed Earnings Play Alerts - mfd.ru
What is Cullinan Therapeutics Inc.’s valuation compared to sectorJuly 2025 Selloffs & Real-Time Stock Price Movement Reports - mfd.ru
Jennifer Michaelson proposes sale of 8,000 shares | CGEM SEC FilingForm 144 - Stock Titan
Cullinan Therapeutics (NASDAQ:CGEM) Research Coverage Started at Citigroup - Defense World
Cullinan Therapeutics Touts 2026 “Defining Year” as T-Cell Engager, Zipalertinib Catalysts Near - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Hits New 1-Year HighTime to Buy? - MarketBeat
CGEM: 2026 will bring major clinical and regulatory milestones across oncology and autoimmune programs - TradingView
Cullinan Therapeutics (NASDAQ:CGEM) Earns Buy Rating from Analysts at Citigroup - MarketBeat
Cullinan Therapeutics (CGEM) Expected to Announce Quarterly Earnings on Thursday - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026 Virtual Oncology Leadership Summit - The Globe and Mail
Cullinan leaders join Citi virtual oncology fireside chat on Feb. 19 - Stock Titan
Citigroup Initiates Coverage of Cullinan Therapeutics (CGEM) with Buy Recommendation - Nasdaq
Citigroup Initiates Buy Coverage on CGEM with $33 Target | CGEM Stock News - GuruFocus
Citigroup Initiates Cullinan Therapeutics at Buy With $33 Price Target - marketscreener.com
Cullinan Therapeutics Inc Stock (CGEM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):